Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Small cell lung carcinoma].

Jean-Louis Pujol1, Xavier Quantin, William Jacot

  • 1Unité d'oncologie thoracique Hôpital Arnaud-de-Villeneuve Centre hospitalier universitaire et Languedoc Mutualité nouvelles technologies 34295 Montpellier. pujol@cyber-sante.org

La Revue Du Praticien
|July 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of return to work in long-term metastatic breast cancer survivors: Results of a multicenter French cohort.

Bulletin du cancer·2026
Same author

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Nature communications·2026
Same author

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Cancer communications (London, England)·2026
Same author

SLFN11 expression as a marker of small cell lung cancer vulnerability to combined PARP inhibitors and immune checkpoint inhibitors during maintenance.

Journal of thoracic disease·2026
Same author

Prognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohort.

Breast cancer research : BCR·2026
Same author

Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women.

Breast (Edinburgh, Scotland)·2026

Small cell lung cancer (SCLC) is often diagnosed at an advanced stage, making chemotherapy the primary treatment. Recommended chemotherapy regimens include cisplatin and VP-16 combinations for extensive disease.

Area of Science:

  • Oncology
  • Medical Science

Context:

  • Small cell lung cancer (SCLC) frequently presents at the extensive disease stage, indicating widespread metastasis.
  • The micrometastatic nature of SCLC often implies a metastatic disease at diagnosis.

Purpose:

  • To outline the established therapeutic strategies for small cell lung cancer based on disease stage.
  • To highlight the role of chemotherapy as the primary treatment modality for SCLC.

Summary:

  • Chemotherapy, particularly cisplatin and VP-16 combinations, is the cornerstone for treating SCLC.
  • For extensive disease SCLC, chemotherapy alone is the recommended treatment.
  • Limited disease SCLC is treated with radiochemotherapy, with concomitant or alternate modalities being acceptable.
  • Prophylactic cranial irradiation is advised for complete responders with initially limited disease.

Related Experiment Videos

Impact:

  • Establishes chemotherapy as the standard of care for extensive stage SCLC.
  • Defines the role of radiochemotherapy and other modalities for limited stage SCLC.
  • Recommends prophylactic cranial irradiation to improve outcomes in specific SCLC patient groups.